[go: up one dir, main page]

WO2006023659A3 - Novel polymorphs of azabicyclohexane - Google Patents

Novel polymorphs of azabicyclohexane Download PDF

Info

Publication number
WO2006023659A3
WO2006023659A3 PCT/US2005/029420 US2005029420W WO2006023659A3 WO 2006023659 A3 WO2006023659 A3 WO 2006023659A3 US 2005029420 W US2005029420 W US 2005029420W WO 2006023659 A3 WO2006023659 A3 WO 2006023659A3
Authority
WO
WIPO (PCT)
Prior art keywords
forms
polymorph
azabicyclohexane
polymorph form
novel polymorphs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/029420
Other languages
French (fr)
Other versions
WO2006023659A2 (en
Inventor
Eric J Hagen
Kevin Halloran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOV Pharmaceutical Inc
Original Assignee
DOV Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020127030289A priority Critical patent/KR20130004370A/en
Priority to CA002619817A priority patent/CA2619817A1/en
Priority to KR1020137024105A priority patent/KR20130108489A/en
Priority to MX2007001827A priority patent/MX2007001827A/en
Priority to JP2007528015A priority patent/JP2008510715A/en
Priority to AU2005277351A priority patent/AU2005277351A1/en
Priority to BRPI0515193-7A priority patent/BRPI0515193A/en
Priority to EP05785506A priority patent/EP1786417A4/en
Application filed by DOV Pharmaceutical Inc filed Critical DOV Pharmaceutical Inc
Publication of WO2006023659A2 publication Critical patent/WO2006023659A2/en
Publication of WO2006023659A3 publication Critical patent/WO2006023659A3/en
Priority to IL181185A priority patent/IL181185A/en
Anticipated expiration legal-status Critical
Priority to NO20071372A priority patent/NO20071372L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.
PCT/US2005/029420 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane Ceased WO2006023659A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0515193-7A BRPI0515193A (en) 2004-08-18 2005-08-17 new azabicyclohexane polymorphs
KR1020137024105A KR20130108489A (en) 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane
MX2007001827A MX2007001827A (en) 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane.
JP2007528015A JP2008510715A (en) 2004-08-18 2005-08-17 A new polymorph of azabicyclohexane
AU2005277351A AU2005277351A1 (en) 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane
KR1020127030289A KR20130004370A (en) 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane
CA002619817A CA2619817A1 (en) 2004-08-18 2005-08-17 Thermodynamically stable polymorph of an azabicyclohexane
EP05785506A EP1786417A4 (en) 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane
IL181185A IL181185A (en) 2004-08-18 2007-02-06 Composition containing polymorphs a, b and c of azabicyclohexane, said polymorphs, process for their preparation and pharmaceutical compositions containing them
NO20071372A NO20071372L (en) 2004-08-18 2007-03-14 New polymorphs of azabicyclohexane

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92074804A 2004-08-18 2004-08-18
US10/920,748 2004-08-18

Publications (2)

Publication Number Publication Date
WO2006023659A2 WO2006023659A2 (en) 2006-03-02
WO2006023659A3 true WO2006023659A3 (en) 2006-12-07

Family

ID=35968183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029420 Ceased WO2006023659A2 (en) 2004-08-18 2005-08-17 Novel polymorphs of azabicyclohexane

Country Status (14)

Country Link
EP (1) EP1786417A4 (en)
JP (1) JP2008510715A (en)
KR (3) KR20130004370A (en)
CN (1) CN101052393A (en)
AU (1) AU2005277351A1 (en)
BR (1) BRPI0515193A (en)
CA (1) CA2619817A1 (en)
IL (1) IL181185A (en)
MX (1) MX2007001827A (en)
NO (1) NO20071372L (en)
NZ (1) NZ589033A (en)
RU (1) RU2007109817A (en)
WO (1) WO2006023659A2 (en)
ZA (1) ZA200701570B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CN101272781A (en) 2005-07-27 2008-09-24 多夫药品公司 Novel 1-aryl-3-azabicyclo [3.1.0] hexanes: processes for their preparation and their use for the treatment of neuropsychiatric disorders
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
CA2834713A1 (en) * 2010-12-03 2012-06-07 Anthony Alexander Mckinney Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP2994129A4 (en) * 2013-05-07 2017-01-25 Euthymic Bioscience, Inc. Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders
KR101567003B1 (en) 2013-12-27 2015-11-06 경희대학교 산학협력단 Fixing Device for Splinters of a Bone and Drill Assembly for Cutting Splinters of a Bone
US9708261B2 (en) 2015-06-17 2017-07-18 Neurovance, Inc. Crystalline compounds
CN116813547A (en) * 2023-06-29 2023-09-29 爱斯特（成都）生物制药股份有限公司 Method for preparing 3-azabicyclo [3,2,1] octane hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent

Also Published As

Publication number Publication date
NO20071372L (en) 2007-05-18
NZ589033A (en) 2012-06-29
EP1786417A2 (en) 2007-05-23
BRPI0515193A (en) 2008-07-08
CA2619817A1 (en) 2006-03-02
KR20130004370A (en) 2013-01-09
IL181185A (en) 2012-10-31
AU2005277351A1 (en) 2006-03-02
KR20130108489A (en) 2013-10-02
RU2007109817A (en) 2008-09-27
EP1786417A4 (en) 2009-05-20
CN101052393A (en) 2007-10-10
JP2008510715A (en) 2008-04-10
ZA200701570B (en) 2008-08-27
WO2006023659A2 (en) 2006-03-02
KR20070054208A (en) 2007-05-28
MX2007001827A (en) 2007-04-23
IL181185A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
IL160545A0 (en) (-)-1-(3,4-dichlorophenyl) -3- azabicyclo [3.1.0] hexane, compositions thereof and uses as a dopamine-reuptake inhibitor
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
MY141224A (en) Crystalline form of a biphenyl compound
SG170729A1 (en) Processes and intermediates for preparing steric compounds
NO20071372L (en) New polymorphs of azabicyclohexane
TW200510277A (en) Crystalline form of β2-adrenergic receptor agonist
WO2004043920A8 (en) Polymorphs of bicifadine hydrochloride
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
EA200400491A1 (en) POLYMORPHIC FORM OF RIMONABANT, METHOD FOR ITS OBTAINING AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
WO2009141718A3 (en) Process for the preparation of prostaglandin analogues and intermediates thereof
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
EP2404913A3 (en) Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
WO2004074350A3 (en) Bicalutamide polymorphs
EP3020704A3 (en) Crystalline polymorphs of clevidipine butyrate
WO2004050618A8 (en) Crystalline form f of atorvastatin hemi-calcium salt
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2009039362A3 (en) Chiral synthesis of diazepinoquinolines
WO2003004455A3 (en) Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation
WO2006066044A3 (en) Processes for producing 4-aminoquinazolines
WO2007031845A3 (en) Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
WO2005123670A3 (en) Crystalline form of a substituted pyrrolidine compound
WO2005054175A3 (en) New process for the preparation of nitrooxyderivatives of paracetamol
WO2007054969A3 (en) Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
WO2004078109A3 (en) PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181185

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001827

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200580027926.9

Country of ref document: CN

Ref document number: 1274/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12007500398

Country of ref document: PH

Ref document number: 2007528015

Country of ref document: JP

Ref document number: 2005277351

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 553337

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005785506

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005277351

Country of ref document: AU

Date of ref document: 20050817

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005277351

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007109817

Country of ref document: RU

Ref document number: 1020077006293

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005785506

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2619817

Country of ref document: CA

ENP Entry into the national phase

Ref document number: PI0515193

Country of ref document: BR